United States & Gilead Sciences

United States: The United States>>> market now has the first approved treatment for chronic hepatitis delta virus, addressing a significant public health need for an estimated 40,000 to 80,000 people.

Gilead Sciences: The approval of Hepcludex by the United States — Food and Drug Administration>>> expands Gilead Sciences>>>' liver disease portfolio and positions it as a primary player in the hepatitis D treatment market. This approval is a significant commercial advancement for Gilead Sciences>>>.

United States: United States>>> has bolstered precautions, including screening air passengers and suspending visa services, and has provided $13 million in assistance for the response.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

United States: United States>>> proposed establishing an Ebola quarantine facility in Kenya>>> for its citizens exposed to the virus, aiming to prevent Ebola cases from entering its territory. This policy shift has drawn criticism from public health experts and led to a court suspension in Kenya>>>.

Gilead Sciences: Gilead Sciences' antiviral remdesivir is mentioned as a potential treatment to be used at the quarantine facility, indicating its role in the medical response to Ebola.

United States: The United States>>> has announced additional aid to the Democratic Republic of the Congo>>> for the Ebola response and has implemented temporary travel bans for non-citizens from affected countries. It also plans to establish a quarantine facility in Kenya>>> for exposed Americans.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

United States: The United States>>> has pledged financial aid and is monitoring the Ebola outbreak, with some of its citizens exposed or infected, but its previous aid cuts and withdrawal from the World Health Organization>>> have been criticized for weakening global health response capacity.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

Gilead Sciences: Gilead Sciences developed and received approval for lenacapavir (Yeztugo), the twice-a-year HIV prevention shot, which is a significant product for the company.

Gilead Sciences: Gilead Sciences is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.